Industry

Tenpoint Therapeutics Partners With Ritedose to Manufacture Yuvezzi

Vision Monday2d ago1 min read

SEATTLE—The Ritedose Corporation, Inc., a contract development manufacturing organization (CDMO) in the U.S. specializing in sterile Blow-Fill-Seal (BFS) production of unit dose solutions for the ophthalmic and respiratory markets, announced it is partnering with Tenpoint Therapeutics, Ltd. to manufacture Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, the first and only dual-agent eye drop FDA-approved for the treatment of presbyopia. In January of this year, the U.S. Food and Drug Administration (FDA) approved Yuvezzi for the treatment of presbyopia in adults. In late March, Tenpoint announced the commercial launch of Yuvezzi nationwide.

Read full article on Vision Monday

AI Summary

Quick Take

Tenpoint Therapeutics has partnered with The Ritedose Corporation to manufacture Yuvezzi (carbachol 2.75%/brimonidine tartrate 0.1%), the first dual-agent ophthalmic solution for presbyopia. Following its FDA approval in January and a nationwide commercial launch in late March, the drug will be produced using sterile Blow-Fill-Seal technology for unit dose delivery.

Why It Matters

The presbyopia-correcting drop market is evolving beyond pilocarpine-only formulations, and Yuvezzi represents the first combination therapy to reach U.S. clinicians. By pairing a miotic with an alpha-2 agonist, the treatment aims to optimize the pinhole effect while potentially improving comfort and duration compared to single-agent alternatives. This manufacturing partnership is a key operational milestone to ensure the product's availability and quality as it competes for market share in the growing refractive pharmaceutical space.

Key Details

Yuvezzi is the first and only dual-agent eye drop FDA-approved for the treatment of presbyopia in adults.
The formulation combines carbachol 2.75% and brimonidine tartrate 0.1% to improve near vision.
The Ritedose Corporation will handle production using sterile Blow-Fill-Seal (BFS) technology for unit dose solutions.
The partnership supports the nationwide commercial launch of Yuvezzi, which began in late March.
Tenpoint Therapeutics received FDA approval for the drug in January of this year.

Practice Implications

Clinicians can now offer a dual-mechanism pharmaceutical option for presbyopia, which may be particularly relevant for patients who have had suboptimal experiences with single-agent miotics. The unit-dose BFS packaging provides a sterile, preservative-free delivery method that aligns with modern preferences for ocular surface health.

Who's Affected

OptometristsOphthalmologistsPractice OwnersPresbyopia Patients

Evidence StrengthStrong

AI-generated summary — always read the original source for full context

Discussion

No comments yet. Be the first to share your thoughts.